Arcturus Therapeutics Holdings Inc

NASDAQ:ARCT   3:59:51 PM EDT
60.55
+0.41 (+0.68%)
Other Pre-Announcement

Arcturus Therapeutics Reports Q3 Loss Per Share $0.92

Published: 11/09/2020 21:59 GMT
Arcturus Therapeutics Ltd (ARCT) - Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for Arct-810 Phase I Study and Additional Arct-021 Interim Data.
Q3 Revenue $2.3 Million Versus $3.3 Million.
Q3 Loss per Share $0.92.
Q3 Revenue Estimate $3 Million -- Refinitiv Ibes Data (analyst estimates).
Q3 Earnings per Share Estimate $-0.49 -- Refinitiv Ibes Data (analyst estimates).
Our Cash Balance Totaled $307.1 Million As of End of Q3.company's Cash Position is Expected to Be Sufficient to Support Operations for More Than Two Years.